What are Early Access Programs for bispecific antibody therapy? 

Early Access Programs make pre-approved drugs available for patients and physicians outside of a clinical trial. They can be referred to as Expanded Access Programs, Compassionate Use Programs, or Managed Access Programs. 

In the myeloma field, these types of approvals can be key in allowing patients with aggressive and/or quickly relapsing disease to gain access to life-saving medications. As always, it’s important to assess the risks and have an educated discussion with your healthcare team to make sure it’s the right decision for you. 

Listed are the examples of the Expanded Access Programs for the bispecific antibodies available now: 

- Early Access Programs – What To Consider As A Patient

- Elranatamab